{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:39:05Z","timestamp":1787020745152,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["CIFMS 2021-I2M-1-003"],"award-info":[{"award-number":["CIFMS 2021-I2M-1-003"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-059"],"award-info":[{"award-number":["2022-PUMCH-B-059"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Over the past approximately 40 years, Chinese drug regulations have undergone many major reforms to accelerate the approval of drugs and keep pace with the scientific innovation of drugs in the world, especially developed countries. In 2018 and 2023 China\u2019s National Health Commission in collaboration with other departments released China\u2019s \u201cFirst Batch of Rare Diseases Catalogue\u201d and \u201cSecond Batch of Rare Disease Catalogue\u201d. However, there is currently less relevant research on the overview and speed of the approval of rare disease drugs in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study used cross-sectional analysis of rare disease drugs approved in China and the USA from 1983 to 2022 through official drug search databases and systematically analyzed and compared rare disease drugs approved in the USA and China, including the number, approval time, related laws and regulations, and expedited programs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between 1983 and 2022, the USA Food and Drug Administration (FDA) approved a total of 693 orphan drugs (covering 1228 formulations\/specifications). Among these, 201 drugs (425 formulations\/specifications) were approved by China\u2019s National Medical Products Administration (NMPA), accounting for 29.0% (201\/693) of the approved drugs and 34.6%(425\/1228) of the approved formulations\/specifications. The number of China\u2019s rare diseases drugs is increasing year by year, and the approval speed has gradually accelerated. The median approval lag time was 32.3 years (IQR: 22.9\u201333.6) from 1983 to 1987. In contrast, the shortest median lag time occurred between 2018 and 2022, at approximately 1.4 years (IQR: 0.5\u20132.6)\u2014a reduction of 94.2% that reflects the success of China\u2019s ongoing drug regulatory reforms. The special procedures for drug approval have a great promoting effect on rare diseases drugs\u2019 approval.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This research provides evidence of breakthroughs in the review and approval of rare disease drugs in China and demonstrates the tremendous boost to rare disease drugs from China\u2019s ongoing restructuring and reform of the drug regulatory ecosystem, as well as a stimulus for future rare disease drugs development in China.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-04175-4","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T15:16:32Z","timestamp":1766416592000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Trends, lag and characteristics of rare disease drug approval in the USA and China, 1983\u20132022"],"prefix":"10.1186","volume":"20","author":[{"given":"Shaohong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhen","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmei","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2643-0706","authenticated-orcid":false,"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"issue":"9629","key":"4175_CR1","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1016\/S0140-6736(08)60872-7","volume":"371","author":"A Schieppati","year":"2008","unstructured":"Schieppati A, Henter JI, Daina E, Aperia A. Why rare diseases are an important medical and social issue. Lancet. 2008;371(9629):2039\u201341.","journal-title":"Lancet"},{"issue":"4","key":"4175_CR2","doi-asserted-by":"publisher","first-page":"290","DOI":"10.4103\/0975-7406.72128","volume":"2","author":"A Sharma","year":"2010","unstructured":"Sharma A, Jacob A, Tandon M, Kumar D. Orphan drug: development trends and strategies. J Pharm Bioallied Sci. 2010;2(4):290\u20139.","journal-title":"J Pharm Bioallied Sci"},{"key":"4175_CR3","doi-asserted-by":"crossref","unstructured":"Richter T, Nestler-Parr S, Babela R, et al. Rare disease terminology and definitions\u2014a systematic global review: report of the ISPOR rare disease special interest Group. Value Health. 2015. 18(6): 906\u201314.","DOI":"10.1016\/j.jval.2015.05.008"},{"issue":"7","key":"4175_CR4","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nrd3160","volume":"9","author":"MM Braun","year":"2010","unstructured":"Braun MM, Farag-El-Massah S, Xu K, Cot\u00e9 TR. Emergence of orphan drugs in the united states: a quantitative assessment of the first 25 years. Nat Rev Drug Discov. 2010;9(7):519\u201322.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"4175_CR5","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1007\/s43441-019-00071-9","volume":"54","author":"SW Lee","year":"2020","unstructured":"Lee SW, Park SH, Song I, et al. Notable differences in drug lag between Korea and Japan of new drugs between 2009 and 2017. Ther Innov Regul Sci. 2020;54(2):418\u201323.","journal-title":"Ther Innov Regul Sci"},{"key":"4175_CR6","doi-asserted-by":"crossref","unstructured":"Liu BC, He L, He G, He Y. A cross-national comparative study of orphan drug policies in the united States, the European Union, and japan: towards a made-in-China orphan drug policy. J Public Health Policy. 2010. 31(4): 407\u2009\u2013\u200920.","DOI":"10.1057\/jphp.2010.30"},{"issue":"5","key":"4175_CR7","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrd3445","volume":"10","author":"K Westermark","year":"2011","unstructured":"Westermark K, Holm BB, S\u00f6derholm M, et al. European regulation on orphan medicinal products: 10 years of experience and future perspectives. Nat Rev Drug Discov. 2011;10(5):341\u20139.","journal-title":"Nat Rev Drug Discov"},{"key":"4175_CR8","unstructured":"Medicine NHCaTDoIaITDAAoTC. Notice on the publication of the first batch of rare disease catalogues. 2018. https:\/\/www.gov.cn\/zhengce\/zhengceku\/2018-12\/31\/content_5435167.htm."},{"key":"4175_CR9","unstructured":"Notice of publication of the second catalog of rare diseases. Notice of publication of the second catalog of rare diseases. 2023. https:\/\/www.gov.cn\/zhengce\/zhengceku\/202309\/content_6905273.htm."},{"issue":"3","key":"4175_CR10","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/d41573-023-00177-8","volume":"23","author":"R Chen","year":"2024","unstructured":"Chen R, Liu S, Han J, et al. Trends in rare disease drug development. Nat Rev Drug Discov. 2024;23(3):168\u20139.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"4175_CR11","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s10198-023-01639-x","volume":"25","author":"DT Michaeli","year":"2024","unstructured":"Michaeli DT, Michaeli T, Albers S, Boch T, Michaeli JC. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy. Eur J Health Econ. 2024;25(6):979\u201397.","journal-title":"Eur J Health Econ"},{"issue":"1","key":"4175_CR12","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/cpt.2755","volume":"113","author":"X Luo","year":"2023","unstructured":"Luo X, Du X, Li Z, Qian F, Yang Y. Assessment of the delay in novel anticancer drugs between China and the united states: a comparative study of drugs approved between 2010 and 2021. Clin Pharmacol Ther. 2023;113(1):170\u201381.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"4175_CR13","doi-asserted-by":"publisher","first-page":"103578","DOI":"10.1016\/j.drudis.2023.103578","volume":"28","author":"X Luo","year":"2023","unstructured":"Luo X, Guo Q, Du X, Huang L, Chow SC, Yang Y. Evaluation of clinical trial designs for novel anticancer drugs in china: a cohort study of drugs approved between 2015 and 2021. Drug Discov Today. 2023;28(6):103578.","journal-title":"Drug Discov Today"},{"issue":"5","key":"4175_CR14","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1007\/s10637-021-01117-2","volume":"39","author":"X Li","year":"2021","unstructured":"Li X, Yang Y. The drug lag issue: a 20-year review of China. Invest New Drugs. 2021;39(5):1389\u201398.","journal-title":"Invest New Drugs"},{"key":"4175_CR15","unstructured":"A Model of Effective Health Policy."},{"issue":"2","key":"4175_CR16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s43441-022-00472-3","volume":"57","author":"L Su","year":"2023","unstructured":"Su L, Liu S, Li G, et al. Trends and characteristics of new drug approvals in China, 2011\u20132021. Ther Innov Regul Sci. 2023;57(2):343\u201351.","journal-title":"Ther Innov Regul Sci"},{"issue":"1","key":"4175_CR17","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13023-023-02684-8","volume":"18","author":"Z Zhao","year":"2023","unstructured":"Zhao Z, Pei Z, Hu A, Zhang Y, Chen J. Analysis of incentive policies and initiatives on orphan drug development in china: Challenges, reforms and implications. Orphanet J Rare Dis. 2023;18(1):220.","journal-title":"Orphanet J Rare Dis"},{"key":"4175_CR18","doi-asserted-by":"publisher","first-page":"1278710","DOI":"10.3389\/fphar.2024.1278710","volume":"15","author":"M Liu","year":"2024","unstructured":"Liu M, Lu Y, Li J, Zhang Y, Zhang S, Liu Y. Orphan drug policy analysis in China. Front Pharmacol. 2024;15:1278710.","journal-title":"Front Pharmacol"},{"issue":"1","key":"4175_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2190\/9Y32-X86Y-M3F0-JQFC","volume":"22","author":"F Andersson","year":"1992","unstructured":"Andersson F. The drug lag issue: the debate seen from an international perspective. Int J Health Serv. 1992;22(1):53\u201372.","journal-title":"Int J Health Serv"},{"key":"4175_CR20","doi-asserted-by":"crossref","unstructured":"Chen S, Chen X, Liu M, Xu Z, Yang Y. Regulation of generic drugs in china: progress and effect of the reform of the review and approval system. J Pharm Innov. 2022.","DOI":"10.1007\/s12247-022-09655-9"},{"issue":"12","key":"4175_CR21","doi-asserted-by":"publisher","first-page":"103370","DOI":"10.1016\/j.drudis.2022.103370","volume":"27","author":"X Luo","year":"2022","unstructured":"Luo X, Qian F, Yang L, Li Y, Yang Y. Assessment of the breakthrough-therapy-designated drugs granted in china: A pooled analysis 2020\u20132022. Drug Discov Today. 2022;27(12):103370.","journal-title":"Drug Discov Today"},{"key":"4175_CR22","doi-asserted-by":"publisher","first-page":"102177","DOI":"10.1016\/j.eclinm.2023.102177","volume":"63","author":"X Luo","year":"2023","unstructured":"Luo X, Du X, Huang L, et al. Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022. EClinicalMedicine. 2023;63:102177.","journal-title":"EClinicalMedicine"},{"issue":"9","key":"4175_CR23","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/j.clinthera.2020.06.023","volume":"42","author":"X Zhu","year":"2020","unstructured":"Zhu X, Liu B. Launch delay of new drugs in China and effect on patients\u2019 health. Clin Ther. 2020;42(9):1750\u2013e17617.","journal-title":"Clin Ther"},{"issue":"11","key":"4175_CR24","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nrd.2016.200","volume":"15","author":"L Shao","year":"2016","unstructured":"Shao L, Xu L, Li Q, Chakravarthy R, Yang Z, Kaitin KI. Regulatory watch: innovative drug availability in China. Nat Rev Drug Discov. 2016;15(11):739\u201340.","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"4175_CR25","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1080\/21645515.2019.1605809","volume":"15","author":"R Jiang","year":"2019","unstructured":"Jiang R, Sun Y, Ung C, et al. Research and development of mAb drugs in china: a look from policy perspectives. Hum Vaccin Immunother. 2019;15(11):2695\u2013705.","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"4175_CR26","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1016\/j.apsb.2022.08.004","volume":"12","author":"Y Liu","year":"2022","unstructured":"Liu Y, Zhang N, Xie C, et al. Evolution of drug regulations and regulatory innovation for anticancer drugs in China. Acta Pharm Sin B. 2022;12(12):4365\u201377.","journal-title":"Acta Pharm Sin B"},{"issue":"12","key":"4175_CR27","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1038\/nrd.2018.150","volume":"17","author":"L Xu","year":"2018","unstructured":"Xu L, Gao H, Kaitin KI, Shao L. Reforming china\u2019s drug regulatory system. Nat Rev Drug Discov. 2018;17(12):858\u20139.","journal-title":"Nat Rev Drug Discov"},{"key":"4175_CR28","first-page":"100670","volume":"32","author":"X Luo","year":"2023","unstructured":"Luo X, Du X, Huang L, et al. The price, efficacy, and safety of within-class targeted anticancer medicines between domestic and imported drugs in china: a comparative analysis. Lancet Reg Health West Pac. 2023;32:100670.","journal-title":"Lancet Reg Health West Pac"},{"key":"4175_CR29","doi-asserted-by":"crossref","unstructured":"Aslam F, Ali I, Babar Z, Yang Y. Building evidence for improving vaccine adoption and uptake of childhood vaccinations in low- and middle-income countries: a systematic review. Drugs Therapy Perspectives. 2022:38;133\u201345.","DOI":"10.1007\/s40267-021-00890-7"},{"issue":"6","key":"4175_CR30","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1177\/2168479018764661","volume":"52","author":"J Chen","year":"2018","unstructured":"Chen J, Zhao N. Recent advances in drug development and regulatory science in China. Ther Innov Regul Sci. 2018;52(6):739\u201350.","journal-title":"Ther Innov Regul Sci"},{"key":"4175_CR31","doi-asserted-by":"crossref","unstructured":"Luyao Q, Xin L, Junmei S, et al. Evaluating the national system for rare diseases in China from the point of drug access: progress and challenges. Orphanet J Rare Dis. 2022. 17(1).","DOI":"10.1186\/s13023-022-02507-2"},{"issue":"12","key":"4175_CR32","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.jval.2020.06.020","volume":"23","author":"A Chan","year":"2020","unstructured":"Chan A, Chan V, Olsson S, et al. Access and unmet needs of orphan drugs in 194 countries and 6 areas: A global policy review with content analysis. Value Health. 2020;23(12):1580\u201391.","journal-title":"Value Health"},{"key":"4175_CR33","doi-asserted-by":"crossref","unstructured":"Franco P. Orphan drugs: the regulatory environment. Drug Discov Today. 2013. 18(3\u20134): 163\u2009\u2013\u200972.","DOI":"10.1016\/j.drudis.2012.08.009"},{"issue":"1","key":"4175_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5582\/irdr.3.1","volume":"3","author":"AK Hall","year":"2014","unstructured":"Hall AK, Carlson MR. The current status of orphan drug development in Europe and the US. Intractable Rare Dis Res. 2014;3(1):1\u20137.","journal-title":"Intractable Rare Dis Res"},{"issue":"1","key":"4175_CR35","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s13023-020-01568-5","volume":"15","author":"X Li","year":"2020","unstructured":"Li X, Lu Z, Zhang J, et al. The urgent need to empower rare disease organizations in china: an interview-based study. Orphanet J Rare Dis. 2020;15(1):282.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"4175_CR36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/cts.12500","volume":"11","author":"CP Austin","year":"2018","unstructured":"Austin CP, Cutillo CM, Lau L, et al. Future of rare diseases research 2017\u20132027: an IRDiRC perspective. Clin Transl Sci. 2018;11(1):21\u20137.","journal-title":"Clin Transl Sci"},{"issue":"2","key":"4175_CR37","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/hir.12256","volume":"36","author":"SU Weerasooriya","year":"2019","unstructured":"Weerasooriya SU. The impact of orphan drug policies in treating rare diseases. Health Info Libr J. 2019;36(2):179\u201384.","journal-title":"Health Info Libr J"},{"issue":"7","key":"4175_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/15265161.2023.2207500","volume":"23","author":"MC Halley","year":"2023","unstructured":"Halley MC, Halverson C, Tabor HK, Goldenberg AJ. Rare Disease, advocacy and justice: intersecting disparities in research and clinical care. Am J Bioeth. 2023;23(7):17\u201326.","journal-title":"Am J Bioeth"},{"issue":"3","key":"4175_CR39","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.drudis.2012.08.009","volume":"18","author":"P Franco","year":"2013","unstructured":"Franco P. Orphan drugs: the regulatory environment. Drug Discov Today. 2013;18(3):163\u201372.","journal-title":"Drug Discov Today"},{"key":"4175_CR40","doi-asserted-by":"crossref","unstructured":"Ameet S, Beall Reed F, Abdurrahman A, Mengdong H, Kesselheim Aaron S. Evaluating the impact of the orphan drug act\u2019s seven-year market exclusivity period. Health affairs (Project Hope). 2018. 37(5).","DOI":"10.1377\/hlthaff.2017.1179"},{"issue":"2","key":"4175_CR41","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jama.2019.20288","volume":"323","author":"JJ Darrow","year":"2020","unstructured":"Darrow JJ, Avorn J, Kesselheim AS. FDA approval and regulation of Pharmaceuticals, 1983\u20132018. JAMA. 2020;323(2):164\u201376.","journal-title":"JAMA"},{"key":"4175_CR42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1750-1172-3-33","volume":"3","author":"E Seoane-Vazquez","year":"2008","unstructured":"Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach SL, Visaria J. Incentives for orphan drug research and development in the united States. Orphanet J Rare Dis. 2008;3:33.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"4175_CR43","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/cpt.426","volume":"100","author":"ME Haffner","year":"2016","unstructured":"Haffner ME. History of orphan drug Regulation-United States and beyond. Clin Pharmacol Ther. 2016;100(4):342\u20133.","journal-title":"Clin Pharmacol Ther"},{"key":"4175_CR44","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/978-3-319-67144-4_10","volume":"1031","author":"TT Le","year":"2017","unstructured":"Le TT. Incentivizing orphan product development: united States food and drug administration orphan incentive programs. Adv Exp Med Biol. 2017;1031:183\u201396.","journal-title":"Adv Exp Med Biol"},{"key":"4175_CR45","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1750-1172-7-74","volume":"7","author":"W Hughes-Wilson","year":"2012","unstructured":"Hughes-Wilson W, Palma A, Schuurman A, Simoens S. Paying for the orphan drug system: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments. Orphanet J Rare Dis. 2012;7:74.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"4175_CR46","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1377\/hlthaff.2016.0030","volume":"35","author":"V Divino","year":"2016","unstructured":"Divino V, DeKoven M, Kleinrock M, Wade RL, Kaura S. Orphan drug expenditures in the united states: a historical and prospective Analysis, 2007-18. Health Aff (Millwood). 2016;35(9):1588\u201394.","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"4175_CR47","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13023-023-02790-7","volume":"18","author":"LJ Fermaglich","year":"2023","unstructured":"Fermaglich LJ, Miller KL. A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the Forty years of the orphan drug act. Orphanet J Rare Dis. 2023;18(1):163.","journal-title":"Orphanet J Rare Dis"},{"issue":"10149","key":"4175_CR48","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S0140-6736(18)31069-9","volume":"392","author":"L Luzzatto","year":"2018","unstructured":"Luzzatto L, Hyry HI, Schieppati A, et al. Outrageous prices of orphan drugs: a call for collaboration. Lancet. 2018;392(10149):791\u20134.","journal-title":"Lancet"},{"key":"4175_CR49","doi-asserted-by":"crossref","unstructured":"Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health care. 2007;23(1): 36\u201342.","DOI":"10.1017\/S0266462307051550"},{"issue":"1","key":"4175_CR50","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1750-1172-6-42","volume":"6","author":"S Simoens","year":"2011","unstructured":"Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011;6(1):42.","journal-title":"Orphanet J Rare Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04175-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04175-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04175-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T20:55:03Z","timestamp":1767041703000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-025-04175-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4175"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04175-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3647611\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]},"assertion":[{"value":"27 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Declerations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"635"}}